Journal article

Transcriptional Modulation of the Hippo Signaling Pathway by Drugs Used to Treat Bipolar Disorder and Schizophrenia

Bruna Panizzutti, Chiara C Bortolasci, Briana Spolding, Srisaiyini Kidnapillai, Timothy Connor, Mark F Richardson, Trang TT Truong, Zoe SJ Liu, Gerwyn Morris, Laura Gray, Jee Hyun Kim, Olivia M Dean, Michael Berk, Ken Walder

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | MDPI | Published : 2021

Abstract

Recent reports suggest a link between positive regulation of the Hippo pathway with bipolar disorder (BD), and the Hippo pathway is known to interact with multiple other signaling pathways previously associated with BD and other psychiatric disorders. In this study, neuronal-like NT2 cells were treated with amisulpride (10 µM), aripiprazole (0.1 µM), clozapine (10 µM), lamotrigine (50 µM), lithium (2.5 mM), quetiapine (50 µM), risperidone (0.1 µM), valproate (0.5 mM), or vehicle control for 24 h. Genome-wide mRNA expression was quantified and analyzed using gene set enrichment analysis (GSEA), with genes belonging to Hippo, Wnt, Notch, TGF- β, and Hedgehog retrieved from the KEGG database. F..

View full abstract

University of Melbourne Researchers